| mRNA |
YM-155 |
CTRPv2 |
pan-cancer |
AAC |
0.0054 |
0.9 |
| mRNA |
17-AAG |
CCLE |
pan-cancer |
AAC |
0.0065 |
0.9 |
| mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.9 |
| mRNA |
GSK525762A |
CTRPv2 |
pan-cancer |
AAC |
0.0041 |
0.9 |
| mRNA |
XMD11-85h |
GDSC1000 |
pan-cancer |
AAC |
0.0062 |
0.9 |
| mRNA |
TAE684 |
CTRPv2 |
pan-cancer |
AAC |
0.0046 |
0.9 |
| mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.007 |
0.9 |
| mRNA |
VU0155056 |
CTRPv2 |
pan-cancer |
AAC |
0.0049 |
0.9 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0048 |
0.9 |
| mRNA |
CAY10594 |
CTRPv2 |
pan-cancer |
AAC |
-0.0048 |
0.9 |